Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-d14c5d7dea1d2e7785c6d37dbbff6788"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-d14c5d7dea1d2e7785c6d37dbbff6788"/>
<resource>
<Composition>
<id value="composition-en-d14c5d7dea1d2e7785c6d37dbbff6788"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-d14c5d7dea1d2e7785c6d37dbbff6788"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-d14c5d7dea1d2e7785c6d37dbbff6788</b></p><a name="composition-en-d14c5d7dea1d2e7785c6d37dbbff6788"> </a><a name="hccomposition-en-d14c5d7dea1d2e7785c6d37dbbff6788"> </a><a name="composition-en-d14c5d7dea1d2e7785c6d37dbbff6788-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/870/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - orphacol</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/870/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpd14c5d7dea1d2e7785c6d37dbbff6788"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - orphacol"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Orphacol is and what it is used for</li><li>What you need to know before you take Orphacol</li><li>How to take Orphacol</li><li>Possible side effects</li><li>How to store Orphacol</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What orphacol is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What orphacol is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Orphacol contains cholic acid, a bile acid which is normally produced by the liver. Certain medical conditions are caused by defects in bile acid production and Orphacol is used to treat infants from one month to 2 years of age, children, adolescents and adults with these medical conditions. The cholic acid contained in Orphacol replaces the bile acids that are missing due to the defect in bile acid production.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take orphacol"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take orphacol"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Orphacol</p><ul><li>if you are allergic to cholic acid or any of the other ingredients of this medicine (listed in section 6).</li><li>if you are taking phenobarbital or primidone, a medicine to treat epilepsy.</li></ul><p>Warnings and precautions During your treatment, your doctor will carry out various blood and urine tests at different time to see how your body is handling this medicine and to help work out the dose that you need. More frequent tests will be needed if you are growing fast, if you are ill (if you have e.g. liver problems), or if you are pregnant.</p><p>Other medicines and Orphacol Tell your doctor or pharmacist if you are taking, have recently taken any or might take other medicines.</p><p>Some medicines used to lower cholesterol levels, so-called bile acid sequestrants (cholestyramine, colestipol, colesevelam), and medicines to treat heartburn that contain aluminium may lessen the effect of Orphacol. If you take these medicines, take Orphacol at least 5 hours before or at least 5 hours after taking these other medicines.<br/>Ciclosporin (a medicine used to suppress the immune system) may also change the effect of Orphacol. Please tell your doctor if you are taking ciclosporin. Ursodeoxycholic acid may lessen the effect Orphacol if both medicines are taken at the same time. If you are prescribed ursodeoxycholic acid along with Orphacol in single doses, take one product in the morning and the other product in the evening. If you are prescribed divided doses of ursodeoxycholic acid and/or Orphacol, as these products should be administered separately by several hours, please ask for the advice of your doctor or pharmacist about proper sequence of administration.</p><p>Pregnancy and breast-feeding Please consult your doctor if you plan to become pregnant. Take a pregnancy test as soon as you suspect you may be pregnant. It is very important to continue taking Orphacol during pregnancy.</p><p>If you become pregnant during treatment with Orphacol, your doctor will decide which treatment and dose is best in your situation. As a precaution, you and your unborn child should be closely monitored during pregnancy.</p><p>Orphacol can be used during breast-feeding. Tell your doctor if you plan to breast-feed or are breast- feeding before you take Orphacol.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Driving and using machines Orphacol is not expected to have an effect on the ability to drive and use machines.</p><p>Orphacol contains lactose Orphacol contains a certain sugar (lactose monohydrate). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Orphacol.</p></div>
</text>
</section>
<section>
<title value="3. How to take orphacol"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take orphacol"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take Orphacol exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>The usual starting dose is 5 to 15 mg per kilogram body weight every day in infants, children, adolescents and adults.</p><p>Before treatment your doctor will make an assessment from your laboratory tests to determine the correct dose for you. The dose will then be further adjusted by your doctor depending on your body s response.</p><p>Orphacol capsules are taken by mouth with a meal at approximately the same time each day, in the morning and/or evening. Taking Orphacol at regular times with a meal will help you remember to take this medicine, and may help your body to better take it up. Capsules must be swallowed whole with water. Do not chew.</p><p>If your doctor has prescribed a dose which requires you to take more than one capsule per day, you and your doctor can decide how this will be taken during the day. You may for example take one capsule in the morning and one in the evening. This way, you will have to take fewer capsules at once. However, this might not be possible if you have been prescribed at the same time another medicine containing ursodeoxycholic acid. In this case, you should seek advice from your doctor or pharmacist about proper sequence of administration of ursodeoxycholic acid and Orphacol over the day, as these products should be administered separately by several hours (see section 2). Use in children For babies and children who cannot swallow capsules, the capsule can be opened and its contents added to baby formula or apple/orange or apple/apricot juice adapted for small children.</p><p>If you take more Orphacol than you should If you have taken more Orphacol than you should, contact your doctor as soon as possible. He will assess your laboratory test results and advise you when you should resume your treatment with your normal dose.</p><p>If you forget to take Orphacol Take your next dose when you would normally take it. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Orphacol There is a risk of permanently damaging your liver if you stop taking Orphacol. You should never stop taking Orphacol unless your doctor advises you to do so.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Several patients have experienced itching and/or diarrhoea, however, it is not known how likely this is to occur (frequency cannot be estimated from the available data). If itching and/or diarrhoea last for more than three days, tell your doctor.</p><p>For several patients an increase of liver enzymes (serum transaminases) have been reported during the treatment with Orphacol (frequency cannot be estimated from the available data). Your doctor will decide what to do if this happens to you.</p><p>Gallstones have been reported after long-term therapy with Orphacol.</p><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store orphacol"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store orphacol"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep out of the reach and sight of children.</p><p>Do not use Orphacol after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>Store below 30 C.</p><p>Medicines should not be disposed of via wasterwater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Orphacol contains</p><ul><li>The active substance is cholic acid.<br/>Orphacol 50 mg: Each hard capsule contains 50 mg of cholic acid. Orphacol 250 mg: Each hard capsule contains 250 mg of cholic acid.</li><li>The other ingredients are: Content of capsules: Lactose monohydrate (see section 2 under Orphacol contains lactose for more information), colloidal anhydrous silica, magnesium stearate Capsule shell:<br/>Orphacol 50 mg: gelatin, titanium dioxide (E171), carmine blue (E132); Orphacol 250 mg: gelatin, titanium dioxide (E171), carmine blue (E132), yellow iron oxide (E172).</li></ul><p>What Orphacol looks like and contents of the pack Orphacol is available as hard capsules (capsules) of oblong shape. Capsules of 50 mg cholic acid are blue and white and capsules of 250 mg cholic acid are green and white. They are contained in blisters of 10 capsules each. Pack sizes are available in 30, 60 and 120 capsules. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer</p><p>Marketing Authorisation Holder THERAVIA 16 Rue Montrosier 92200 Neuilly-sur-Seine France</p><p>Manufacturer THERAVIA 16 Rue Montrosier 92200 Neuilly-sur-Seine France</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien THERAVIA T l/Tel: +32 (0)2 40 11 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Lietuva Immedica Pharma AB Tel/Puh: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a></p><p>THERAVIA Te .: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Luxembourg/Luxemburg THERAVIA T l/Tel: +352 278 62 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>esk republika THERAVIA Tel.: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Magyarorsz g Medis Hungary Kft Tel: +36 (2) 380 <a href="mailto:1info@medis.hu">1info@medis.hu</a></p><p>Danmark Immedica Pharma AB<br/>Tlf: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a></p><p>Malta THERAVIA Tel: +356 2776 <a href="mailto:1question@theravia.com">1question@theravia.com</a></p><p>Deutschland THERAVIA Tel: +49 (0)<a href="mailto:3022153question@theravia.com">3022153question@theravia.com</a></p><p>Nederland THERAVIA Tel: +31 (0)2 070 38 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Eesti Immedica Pharma AB<br/>Tel/Puh: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a></p><p>Norge Immedica Pharma AB Tel/Puh: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a></p><p>THERAVIA : +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a><br/>sterreich THERAVIA Tel: +43 (0) 800 909 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Espa a THERAVIA Tel: + (34) 914 146 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Polska THERAVIA Tel.: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>France THERAVIA T l: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Portugal THERAVIA Tel: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Hrvatska Medis Adria d.o.o. Tel: +385 (1) 230 <a href="mailto:3info@medisadria.hr">3info@medisadria.hr</a></p><p>Rom nia THERAVIA Tel: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Ireland THERAVIA Tel: +353 (0)1 695 00 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Slovenija Medis d.o.o. Tel: +386 (1) 589 <a href="mailto:6info@medis.si">6info@medis.si</a></p><p>sland Immedica Pharma AB S mi: + 46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a> Slovensk republika THERAVIA Tel: +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Italia THERAVIA Tel: +39 (0)800 959 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Suomi/Finland Immedica Pharma AB Tel/Puh: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a></p><p>THERAVIA : +33 (0)1 72 69 01 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>Sverige Immedica Pharma AB<br/>Tel: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a> Latvija Immedica Pharma AB Tel: +46 (0)8 533 39 <a href="mailto:info@immedica.com">info@immedica.com</a> United Kingdom (Northern Ireland) THERAVIA Tel: +44 (0)3 301 002 <a href="mailto:question@theravia.com">question@theravia.com</a></p><p>This leaflet was last revised in</p><p>This medicine has been authorised under Exceptional Circumstances . This means that because of the rarity of this disease and for ethical reasons it has been impossible to get complete information on this medicine. The European Medicines Agency will review any new information on the medicine every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpd14c5d7dea1d2e7785c6d37dbbff6788"/>
<resource>
<MedicinalProductDefinition>
<id value="mpd14c5d7dea1d2e7785c6d37dbbff6788"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpd14c5d7dea1d2e7785c6d37dbbff6788"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpd14c5d7dea1d2e7785c6d37dbbff6788</b></p><a name="mpd14c5d7dea1d2e7785c6d37dbbff6788"> </a><a name="hcmpd14c5d7dea1d2e7785c6d37dbbff6788"> </a><a name="mpd14c5d7dea1d2e7785c6d37dbbff6788-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/13/870/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Orphacol 50 mg hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/13/870/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Orphacol 50 mg hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
